GURU.Markets stock price, segment price, and overall market index valuation
The company's share price LB Pharmaceuticals Inc
The shares of LB Pharmaceuticals, a biotech company focused on treating central nervous system disorders, reflect the potential of its scientific platform. The post-IPO price will depend on progress in clinical trials.
Share prices of companies in the market segment - Pharma psycho
LB Pharmaceuticals is a clinical-stage biotechnology company developing new drugs for the treatment of central nervous system disorders, particularly schizophrenia. We've classified it in the "Pharma Psycho" segment. The chart below shows the overall dynamics of this complex yet socially significant pharmaceutical sector.
Broad Market Index - GURU.Markets
LB Pharmaceuticals is a biopharmaceutical company developing drugs to treat central nervous system disorders associated with sleep disorders. As a component of the GURU.Markets index, it represents the biotech sector. The chart below represents the entire market. See how LB Pharma shares compare to the overall trend.
Change in the price of a company, segment, and market as a whole per day
LBRX - Daily change in the company's share price LB Pharmaceuticals Inc
For LB Pharmaceuticals, a biopharmaceutical company, change_co is a measure of the sector's inherently high volatility. Each daily change reflects sensitivity to news about clinical trials of its drugs. This metric isn't just noise, but a critical component of the models on System.GURU.Markets that assess risk in innovative medicine.
Daily change in the price of a set of shares in a market segment - Pharma psycho
LB Pharmaceuticals Inc. is a biotech company. This chart demonstrates the sector's extreme volatility. Comparison with LBRX's performance, which depends on clinical trial results, helps assess it as a high-risk asset.
Daily change in the price of a broad market stock, index - GURU.Markets
LB Pharmaceuticals is a biopharmaceutical company specializing in drugs for the treatment of diseases of the central nervous system. Neuroscience is a risky area of research. The chart below illustrates the high volatility typical of the biotech sector, reflecting the stakes associated with LB's developments.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization LB Pharmaceuticals Inc
LB Pharmaceuticals Inc.'s year-to-date performance is a story about the development of a new drug for schizophrenia. As a clinical-stage company, its 12-month market cap is entirely dependent on the results of trials of its lead candidate, which promises to improve cognitive function in patients, a significant unmet need.
Annual dynamics of market capitalization of the market segment - Pharma psycho
LB Pharma, a private biotech company, develops drugs for the treatment of central nervous system diseases. Its growth depends on success in clinical trials. Its valuation reflects investor confidence in its scientific platform, potentially outperforming the overall pharmaceutical sector, but with higher risks.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
LB Pharmaceuticals is privately held and not publicly traded. Its market performance cannot be analyzed. As a biotech company focused on treating CNS diseases, its value is determined solely by clinical trial results and scientific breakthroughs, not by economic factors.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization LB Pharmaceuticals Inc
As a biopharmaceutical company, LB Pharma's performance will be speculative. Monthly fluctuations on the chart will reflect not revenue, but rather news about the progress of its clinical trials for mental health medications, which will determine its future.
Monthly dynamics of market capitalization of the market segment - Pharma psycho
LB Pharmaceuticals is a biotech company specializing in drugs for the treatment of mental disorders such as schizophrenia with fewer side effects. The chart of the pharmaceutical sector focused on neuropsychiatry will show the overall investor interest in this socially significant yet complex therapeutic area.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
LB Pharmaceuticals is a company developing drugs for the treatment of neuropsychiatric disorders. This is a highly specialized segment of biotech. Its stock price is virtually unrelated to the market and depends entirely on the success of clinical trials. The chart shows how expectations of a treatment breakthrough influence the stock price more than any market trends.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization LB Pharmaceuticals Inc
LB Pharmaceuticals, which develops drugs to treat mental disorders, operates in a complex and socially significant field. Its weekly stock price depends on the results of clinical trials, which are particularly unpredictable in neuroscience, resulting in sharp price fluctuations.
Weekly dynamics of market capitalization of the market segment - Pharma psycho
Biotech companies developing drugs for mental disorders, like LB Pharmaceuticals, operate in a complex and socially significant field. The chart below shows the general sentiment in this niche. It allows one to assess how promising the market perceives LB Pharmaceuticals' approach compared to competitors' developments.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
LB Pharmaceuticals is a biotech company developing drugs to treat sleep disorders and other central nervous system conditions. Its shares are in the realm of clinical trials. The chart shows how their performance depends solely on internal news, rather than on overall market movements.
Market capitalization of the company, segment and market as a whole
LBRX - Market capitalization of the company LB Pharmaceuticals Inc
LB Pharmaceuticals' market capitalization reflects investors' bets on its new approaches to treating mental disorders. The chart reflects the market's belief in the potential of its leading drug for schizophrenia. Its performance will be highly sensitive to clinical trial results, which could offer new hope for millions of patients.
LBRX - Share of the company's market capitalization LB Pharmaceuticals Inc within the market segment - Pharma psycho
LB Pharmaceuticals is focused on developing drugs for the treatment of neuropsychiatric disorders. In this narrow segment, its market capitalization is entirely dependent on investors' faith in the scientific potential of its developments. Any news about clinical trials causes sharp fluctuations in this metric, reflecting the high risks and potential rewards in this field.
Market capitalization of the market segment - Pharma psycho
Below is a chart showing the total value of the entire pharmaceutical sector focused on treating mental disorders. For LB Pharmaceuticals, which operates in this complex field, this line represents a map of hopes and risks. Its dynamics reflect the extent to which investors are willing to invest in lengthy and expensive research for a breakthrough in treating brain diseases.
Market capitalization of all companies included in a broad market index - GURU.Markets
LB Pharmaceuticals is a company developing drugs for the treatment of mental disorders, particularly schizophrenia. Its market capitalization reflects the hope for a new approach in a very complex area of medicine. This represents the market share of mental health.
Book value capitalization of the company, segment and market as a whole
LBRX - Book value capitalization of the company LB Pharmaceuticals Inc
LB Pharmaceuticals is a company developing drugs for the treatment of neuropsychiatric disorders. Its book value is its financial reserves, consisting of the cash needed to conduct clinical trials. How has this capital changed as the research progressed? The chart below shows this story.
LBRX - Share of the company's book capitalization LB Pharmaceuticals Inc within the market segment - Pharma psycho
LB Pharmaceuticals Inc. focuses on the treatment of central nervous system disorders. Its scientific activities require specialized facilities: a laboratory for synthesizing and testing new psychotherapeutic compounds. The chart shows the company's share of the physical R&D infrastructure in this complex pharmaceutical segment.
Market segment balance sheet capitalization - Pharma psycho
LB Pharmaceuticals, a clinical-stage biopharmaceutical company, has minimal physical assets. Its business is focused on R&D. The BCap_Seg chart for the biotech sector, which consists of hundreds of similar companies, is generally low, as the primary capital here is intellectual capital.
Book value of all companies included in the broad market index - GURU.Markets
LB Pharmaceuticals' book value is derived from its intellectual property and clinical trial data for its schizophrenia drug. The company's assets are the capitalized results of years of research in the complex field of psychiatry. The chart below shows how these scientific assets are valued.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - LB Pharmaceuticals Inc
LB Pharma's balance sheet is capitalized R&D costs. Its entire market value is a premium on the hope for the success of its unique drug for schizophrenia. The graph is a visualization of these hopes, which will either be confirmed or refuted by the results of clinical trials.
Market to book capitalization ratio in a market segment - Pharma psycho
LB Pharmaceuticals is a company developing drugs for the treatment of mental disorders. This is an extremely complex field. Its high valuation on this chart reflects investors' faith in the potential of its developments, despite the high risk of clinical failure and the long road to market.
Market to book capitalization ratio for the market as a whole
LB Pharmaceuticals is a biotech company developing drugs to treat mental disorders. Its market value depends almost entirely on the success of clinical trials. This is a prime example of how investor expectations create a valuation unrelated to current book value.
Debts of the company, segment and market as a whole
LBRX - Company debts LB Pharmaceuticals Inc
LB Pharmaceuticals, a company developing drugs for the treatment of neuropsychiatric disorders, is in the clinical stage. All of its raised capital is used to fund research and trials. This chart shows how the biotech startup manages its limited resources in the hopes of creating a new, effective treatment for a complex group of diseases.
Market segment debts - Pharma psycho
LB Pharmaceuticals is a clinical-stage company developing drugs for the treatment of psychiatric disorders. As with most biotech companies, R&D funding is provided through equity to avoid the burden of debt before revenue generation. This chart likely shows minimal or no leverage.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio LB Pharmaceuticals Inc
LB Pharmaceuticals is a company developing drugs to treat neuropsychiatric disorders. This is a long and expensive process. This chart shows how much the company relies on debt to finance its clinical research. It is an indicator of financial risk, which directly correlates with the likelihood of success of its research.
Market segment debt to market segment book capitalization - Pharma psycho
LB Pharmaceuticals is a clinical-stage company focused on developing drugs for the treatment of central nervous system disorders. Psychiatry is one of the most complex areas of R&D. The chart shows how aggressively the biotech sector uses debt, providing context for assessing LB Pharmaceuticals' risks and potential.
Debt to book value of all companies in the market
LB Pharmaceuticals, focused on neuropsychiatric disorders, is in clinical development, requiring a constant influx of capital. This chart, showing the market's overall debt load, provides important context. It allows one to appreciate how the company's financial model is typical of biotech, where revenue is deferred for years and R&D costs are high.
P/E of the company, segment and market as a whole
P/E - LB Pharmaceuticals Inc
LB Pharmaceuticals is a biotech company developing new treatments for neuropsychiatric disorders such as schizophrenia. This chart shows the company's price-to-earnings ratio, which is not its primary metric. Its valuation is based on the scientific potential of its developments and the hope of creating more effective and safer drugs.
P/E of the market segment - Pharma psycho
LB Pharmaceuticals develops drugs to treat neuropsychiatric disorders. This chart shows the average valuation for the biotech sector. It serves as a backdrop for LB Pharma's valuation: investors look not at its profits, but at the potential of its developments in this complex but vast therapeutic area.
P/E of the market as a whole
LB Pharmaceuticals Inc. is a biopharmaceutical company specializing in developing new treatments for neuropsychiatric disorders, such as schizophrenia. This chart reflects the overall risk appetite of investors in the biotech sector. It helps understand whether LBRX's valuation is based on the potential of its drugs or whether it moves in line with overall industry sentiment.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company LB Pharmaceuticals Inc
LB Pharmaceuticals is a company developing drugs for the treatment of central nervous system disorders, particularly schizophrenia. Future profits depend on the results of clinical trials. This chart illustrates investor hopes that the company will be able to offer a new, effective solution for this complex mental illness.
%20P%2FE%20LB%20Pharmaceuticals%20Inc&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-LB-Pharmaceuticals-Inc&v=1772513597144 "Chart of the company's future (projected) P/E LB Pharmaceuticals Inc")
Future (projected) P/E of the market segment - Pharma psycho
LB Pharmaceuticals is a biotech company focused on developing drugs to treat mental disorders such as schizophrenia without serious side effects. The data here reflects analysts' collective bets on the success of its lead candidate. It's a barometer of breakthrough expectations in the highly complex field of psychiatry.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20psycho&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-psycho&v=1772513597161 "Future (projected) P/E graph of the market segment - Pharma psycho")
Future (projected) P/E of the market as a whole
LB Pharmaceuticals is a clinical-stage company developing drugs for the treatment of psychiatric disorders. This graph of overall investor sentiment is critically important, as the availability of capital to fund expensive and lengthy psychiatric trials is directly dependent on market optimism.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772513597177 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit LB Pharmaceuticals Inc
LB Pharmaceuticals is a company specializing in drug development for the treatment of neuropsychiatric disorders. This chart shows the financial investments being made in solving complex medical problems. It reflects the costs of clinical trials, where each stage brings the company closer to, or further away from, the development of an effective therapy and future profits.
Profit of companies in the market segment - Pharma psycho
LB Pharmaceuticals is a biopharmaceutical company specializing in the development of drugs for the treatment of neuropsychiatric disorders. As a clinical-stage company, it invests in solving complex medical problems. Its potential profitability depends on success in clinical trials, reflecting the high risks and potential rewards in this segment of the pharmaceutical industry.
Overall market profit
LB Pharmaceuticals is a biotech company developing drugs to treat mental disorders. The need for such drugs is enormous and is not dependent on the economic situation. However, as with any biotech in development, the overall market conditions, reflected in this chart, critically impact the company's ability to attract research funding.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company LB Pharmaceuticals Inc
LB Pharmaceuticals is a biotech company specializing in developing drugs for the treatment of neuropsychiatric disorders, such as schizophrenia. This chart shows analysts' speculative expectations. The forecast depends entirely on the clinical trial results of their lead candidates and the potential for a breakthrough in the complex field of psychiatry.
%20profit%20of%20the%20company%20LB%20Pharmaceuticals%20Inc&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-LB-Pharmaceuticals-Inc&v=1772513597223 "Graph of future (projected) profit of the company LB Pharmaceuticals Inc")
Future (predicted) profit of companies in the market segment - Pharma psycho
LB Pharmaceuticals is a company specializing in developing drugs to treat mental disorders such as schizophrenia. The profitability forecasts for the pharmaceutical industry, shown on the chart, provide a general overview. This chart helps assess the potential of the company's drugs in an area with a huge unmet medical need.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20psycho&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-psycho&v=1772513597232 "Graph of future (predicted) profits of companies in a market segment - Pharma psycho")
Future (predicted) profit of the market as a whole
LB Pharmaceuticals is a company developing medications for the treatment of mental disorders such as schizophrenia. The need for such medications exists regardless of the state of the economy. However, research funding and future drug prices may depend on the overall economic situation and healthcare system budgets, which are affected by the forecast presented here.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772513597244 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - LB Pharmaceuticals Inc
LB Pharmaceuticals is a biopharmaceutical company specializing in the treatment of neuropsychiatric disorders. Being in the clinical stage, it may not generate significant revenue. This chart shows how investors view its scientific approach and the potential of its drug candidates in an area with a high unmet medical need.
P/S market segment - Pharma psycho
LB Pharmaceuticals is a biopharmaceutical company specializing in the development of innovative treatments for mental disorders such as schizophrenia. This chart shows the average revenue estimate in the pharmaceutical industry. It helps understand the market potential for the company's drugs for the treatment of complex CNS disorders.
P/S of the market as a whole
LB Pharmaceuticals is a biopharmaceutical company developing drugs for the treatment of central nervous system disorders, such as schizophrenia. The company is in clinical trials. This chart shows how the market values companies based on current revenues, providing a backdrop for analyzing the biotech sector.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company LB Pharmaceuticals Inc
LB Pharmaceuticals is a biotech company developing drugs to treat mental disorders such as schizophrenia. This chart reflects investor estimates of its potential future revenue. This estimate depends on the success of clinical trials and the need for new, more effective treatments.
%20P%2FS%20LB%20Pharmaceuticals%20Inc&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-LB-Pharmaceuticals-Inc&v=1772513597274 "The graph of the company's future (projected) P/S LB Pharmaceuticals Inc")
Future (projected) P/S of the market segment - Pharma psycho
LB Pharmaceuticals is a biotech company specializing in developing treatments for central nervous system disorders, such as schizophrenia. This chart compares market expectations for its future revenue with those of other psychopharmaceutical companies. The valuation reflects investor expectations for the success of its clinical programs.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20psycho&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-psycho&v=1772513597279 "Future (projected) P/S market segment graph - Pharma psycho")
Future (projected) P/S of the market as a whole
LB Pharmaceuticals is a clinical-stage biotech company focused on developing drugs to treat mental disorders such as schizophrenia. Its valuation depends on the success of clinical trials. This chart of overall market expectations for LB Pharma is merely a backdrop, as its potential is determined by medical needs, not economics.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772513597292 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales LB Pharmaceuticals Inc
This chart shows the revenue of LB Pharmaceuticals, a company developing drugs to treat mental disorders such as schizophrenia. Being in the clinical stage, it likely has no sales revenue. The chart confirms that the company is fully focused on research, and its value is determined by the potential of its drug candidates and the results of clinical trials.
Sales of companies in the market segment - Pharma psycho
LB Pharmaceuticals is a biopharmaceutical company focused on developing new treatments for mental disorders, particularly schizophrenia, with fewer side effects. This chart shows revenue in the psychopharmaceuticals sector. It reflects the enormous need for more advanced medications for mental illnesses, where LB Pharma's innovations can improve patients' lives.
Overall market sales
LB Pharmaceuticals is a biotech company developing drugs for the treatment of neuropsychiatric disorders. The need for such medications is enormous and is independent of economic conditions. However, overall economic growth, reflected in this graph, impacts government funding for healthcare and mental health care, which is important for future patient access to treatment.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company LB Pharmaceuticals Inc
LB Pharmaceuticals is a clinical-stage biopharmaceutical company specializing in the treatment of neuropsychiatric disorders. This projected revenue chart reflects expectations for its lead drug candidate. The metric's dynamics are entirely dependent on analysts' confidence in the successful results of future clinical trials and potential market launch.
%20sales%20of%20the%20company%20LB%20Pharmaceuticals%20Inc&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-LB-Pharmaceuticals-Inc&v=1772513597316 "Schedule of future (projected) sales of the company LB Pharmaceuticals Inc")
Future (projected) sales of companies in the market segment - Pharma psycho
LB Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing new treatments for mental disorders such as schizophrenia. This chart shows projected revenues for the entire psychopharmaceutical sector, reflecting the critical need for more effective and safe medications for the treatment of mental illnesses.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20psycho&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-psycho&v=1772513597317 "Schedule of future (projected) sales of companies in the market segment - Pharma psycho")
Future (projected) sales of the market as a whole
LB Pharmaceuticals is a biotechnology company specializing in the development of drugs for the treatment of central nervous system disorders. Its success depends on the results of clinical trials. A positive economic environment is essential for attracting the investment needed to fund long-term and complex psychiatric research.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772513597321 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality LB Pharmaceuticals Inc
LB Pharmaceuticals is a company focused on developing drugs for the treatment of neuropsychiatric disorders. While in the clinical stage, it does not yet have any commercial products. This chart illustrates the financial side of science: it shows how much the company invests in research and development to solve complex medical problems.
Market segment marginality - Pharma psycho
LB Pharmaceuticals is a biopharmaceutical company developing drugs for the treatment of neuropsychiatric disorders. This chart shows its operational efficiency relative to other biotech companies in development. Its superiority over competitors may be due to upfront payments from partners or more cost-effective research.
Market marginality as a whole
LB Pharmaceuticals is a biotech company specializing in developing treatments for central nervous system disorders, such as schizophrenia. The need for effective medications to treat mental illnesses is enormous and is not dependent on the economic situation, as reflected in this chart. The company's success is entirely determined by the results of clinical trials.
Employees in the company, segment and market as a whole
Number of employees in the company LB Pharmaceuticals Inc
LB Pharmaceuticals is a clinical-stage company specializing in developing drugs for the treatment of neuropsychiatric disorders. This graph shows a small, focused team. The team size reflects the current phase of clinical trials. An increase will indicate progress and preparation for later stages.
Share of the company's employees LB Pharmaceuticals Inc within the market segment - Pharma psycho
LB Pharmaceuticals is a biotech company specializing in developing drugs for the treatment of central nervous system disorders. Like many of its research-stage peers, it has a small, highly specialized team. This underscores its scientific focus: value is created through discovery, not by the size of its workforce.
Number of employees in the market segment - Pharma psycho
LB Pharmaceuticals is a biotech company specializing in developing drugs to treat neuropsychiatric disorders such as schizophrenia. This chart demonstrates the company's focus on one of the most complex areas of medicine. A small team of scientists is working on challenging problems, and the company's progress depends on the results of long-term clinical trials.
Number of employees in the market as a whole
LB Pharmaceuticals is a biotech company specializing in the development of drugs for the treatment of mental disorders. Its staff consists of highly qualified scientists and clinicians. This employment chart highlights that in the field of advanced medicine, hiring dynamics are driven not by the state of the economy, but by scientific breakthroughs and the need for clinical trials.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company LB Pharmaceuticals Inc (LBRX)
LB Pharmaceuticals is a biopharmaceutical company developing drugs with novel mechanisms of action for the treatment of mental disorders, particularly schizophrenia. This chart demonstrates the enormous market value associated with a single scientist. This is a classic example of biotech, where investors evaluate scientific innovation and the potential to solve a major medical problem.
%20of%20the%20company%20LB%20Pharmaceuticals%20Inc%20(LBRX)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-LB-Pharmaceuticals-Inc-LBRX&v=1772513597351 "Chart of market capitalization per employee (in thousands of dollars) of the company LB Pharmaceuticals Inc (LBRX)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma psycho
LB Pharmaceuticals is a biotech company specializing in drugs for the treatment of psychiatric disorders. In this complex field of medicine, this chart reflects the market's faith in the company's scientific approach. A high valuation per employee may indicate that investors see great potential in their research, led by a focused team.
%20by%20market%20segment%20-%20Pharma%20psycho&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-psycho&v=1772513597364 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma psycho")
Market capitalization per employee (in thousands of dollars) for the overall market
LB Pharmaceuticals is a biopharmaceutical company developing drugs for the treatment of central nervous system disorders. This metric reflects a business focused on a complex and broad area of medicine. Its market capitalization is based on the potential of its developments, allowing its small scientific team to command a high valuation from investors.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772513597366 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company LB Pharmaceuticals Inc (LBRX)
LB Pharmaceuticals is a clinical-stage biotech company focused on treating central nervous system (CNS) disorders. They have no products on the market and are unprofitable. This chart shows the loss per employee. This is an indicator of the "burn rate" of capital spent on expensive clinical trials.
%20Chart%20LB%20Pharmaceuticals%20Inc%20(LBRX)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-LB-Pharmaceuticals-Inc-LBRX&v=1772513597369 "Company Profit Per Employee (in thousands of dollars) Chart LB Pharmaceuticals Inc (LBRX)")
Profit per employee (in thousands of dollars) in the market segment - Pharma psycho
LB Pharmaceuticals is a clinical-stage biotech company specializing in rare psychiatric disorders. The company has no profit, only R&D expenses. The average in this chart provides a baseline for R&D spending per employee in this sector, while the LBRX ratio represents their own capital burn rate.
%20in%20the%20market%20segment%20-%20Pharma%20psycho&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-psycho&v=1772513597381 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma psycho")
Profit per employee (in thousands of dollars) for the market as a whole
LB Pharmaceuticals is a biotech company specializing in drugs for the treatment of mental disorders. Like other clinical-stage companies, they invest in R&D rather than profit. This chart reflects the "cost of science"—the investment spent on each employee in the process of developing and testing new drugs.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772513597388 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee LB Pharmaceuticals Inc (LBRX)
LB Pharmaceuticals is a biotech company specializing in the treatment of neuropsychiatric disorders. This schedule is typical for a clinical-stage company. The lack of revenue per employee means the company is fully focused on research and development of its drug candidates.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-LB-Pharmaceuticals-Inc-LBRX&v=1772513597389 "Sales chart per company employee LB Pharmaceuticals Inc (LBRX)")
Sales per employee in the market segment - Pharma psycho
LB Pharmaceuticals (LBRX) is a biotech company specializing in developing drugs to treat central nervous system (CNS) disorders, such as schizophrenia. This chart shows the revenue (if any) generated by each employee (scientist). It reflects the productivity of their R&D platform in the complex niche of psychiatric diseases compared to other biotechs.
Sales per employee for the market as a whole
LB Pharmaceuticals Inc. is a biopharmaceutical company specializing in the development of drugs for the treatment of mental disorders (schizophrenia). It is a clinical-stage R&D company. The company has no commercial revenue from drug sales. This metric is currently close to zero and does not reflect operating activities.
Short shares by company, segment and market as a whole
Shares shorted by company LB Pharmaceuticals Inc (LBRX)
LB Pharmaceuticals is a biotech company developing drugs to treat central nervous system disorders such as schizophrenia. This chart shows bearish bets. Bears are betting on an extremely high risk of failure in this complex therapeutic area, where trial failures are common.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-LB-Pharmaceuticals-Inc-LBRX&v=1772513597399 "Short Shares Chart for the Company LB Pharmaceuticals Inc (LBRX)")
Shares shorted by market segment - Pharma psycho
LB Pharmaceuticals is a biotech company developing drugs to treat mental and neurological disorders, such as schizophrenia. This chart shows bearish bets. The "shorts" here represent investors betting on the failure of their clinical trials in one of the most complex areas of medicine.
Shares shorted by the overall market
LB Pharmaceuticals specializes in the treatment of neuropsychiatric disorders. This is a complex area with a high demand for new drugs. This chart shows the general level of market fear. Biotech is always risky, and when general pessimism increases, investors can lose the patience needed for lengthy clinical development.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator LB Pharmaceuticals Inc (LBRX)
LB Pharmaceuticals is a clinical-stage biotech. The stock is extremely sensitive to trial news. This chart can surge above 70 on positive R&D data. Oversold territory (<30) often reflects research setbacks or general risk aversion in biotech.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-LB-Pharmaceuticals-Inc-LBRX&v=1772513597412 "RSI 14 indicator chart for the company's stock LB Pharmaceuticals Inc (LBRX)")
RSI 14 Market Segment - Pharma psycho
LB Pharmaceuticals (LBRX) is a biotech company focused on *psychiatry* (schizophrenia). The RSI_14_Seg for "Pharma psycho" (biotech) shows the overall sentiment. The chart helps us understand: is LBRX's volatility a reaction to its clinical trials, or is the entire sector overheated (or oversold)?
RSI 14 for the overall market
LB Pharmaceuticals (LBRX) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria offers the potential to easily raise hundreds of millions of dollars for research. Market panic risks running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast LBRX (LB Pharmaceuticals Inc)
LB Pharmaceuticals (LBRX) is a clinical-stage biotech focused on treating psychiatric conditions such as schizophrenia. This chart shows the average 12-month forecast. It reflects analysts' confidence in the company's scientific platform and their assessment of the likelihood of success in clinical trials.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-LBRX-LB-Pharmaceuticals-Inc&v=1772513597434 "A chart showing analyst consensus forecasts for the expected stock price. LBRX (LB Pharmaceuticals Inc)")
The difference between the consensus estimate and the actual stock price LBRX (LB Pharmaceuticals Inc)
LB Pharmaceuticals is a clinical-stage biotech focused on the treatment of severe mental disorders, primarily schizophrenia. This chart reflects analysts' speculative expectations for their lead drug candidate (NCT-501) and its chances of success in this challenging R&D therapeutic segment.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-LBRX-LB-Pharmaceuticals-Inc&v=1772513597437 "A chart showing the difference between the consensus forecast and the actual stock price. LBRX (LB Pharmaceuticals Inc)")
Analyst consensus forecast for stock prices by market segment - Pharma psycho
LB Pharmaceuticals is a biotech company developing new treatments for mental disorders (such as schizophrenia) with fewer side effects. This chart shows analysts' overall expectations for the psychopharmacology sector. It reflects whether experts believe breakthroughs in the treatment of complex mental illnesses are possible.
Analysts' consensus forecast for the overall market share price
LB Pharmaceuticals (LBRX) is a clinical-stage biopharmaceutical company focused on treating mental disorders such as schizophrenia. This chart shows the overall risk appetite in the market, reflecting the willingness of investors to fund long-term and extremely risky R&D projects in the field of complex brain diseases.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index LB Pharmaceuticals Inc
LB Pharmaceuticals is a clinical-stage biotech company focused on psychiatry. They are developing non-benzodiazepine drugs for the treatment of anxiety disorders and depression. This graph represents pure R&D activity. It likely reflects the market's confidence in their scientific approach and their progress in clinical trials in this complex area.
AKIMA Market Segment Index - Pharma psycho
LB Pharmaceuticals (LBRX) is a clinical-stage biotech focused on psychiatry; the company is developing innovative amphetamine-based drugs for the treatment of schizophrenia. This summary metric evaluates R&D. The graph shows the segment average. This is a benchmark: how does this niche (R&D) focus (LBRX) differentiate it from the average pharma company?
The AKIM Index for the overall market
LB Pharmaceuticals is a clinical-stage biotech company developing improved versions of established antipsychotics for the treatment of schizophrenia. This chart, reflecting the market average, provides a macro backdrop. It helps assess how this strategy of "improving" existing drugs compares to overall economic trends and interest in neuroscience.
